title: Danaparoid in the prevention of thromboembolic complications.
abstract: OBJECTIVE
  To review the therapies used to prevent postoperative thromboembolic complications with a focus on the role of danaparoid, a new low-molecular-weight glycosaminoglycan.
  
  
  METHODS
  A MEDLINE search was performed to identify pertinent English-language literature including studies, abstracts, and review articles. Key search terms included danaparoid, heparinoid, lomoparin, heparin, prophylaxis, thrombosis, embolism, thromboembolism, and thromboembolic and postoperative complications. The manufacturer of danaparoid was contracted for additional information related to this compound.
  
  
  METHODS
  All identified articles were reviewed for possible inclusion in this review. Comparisons primarily focused on data obtained from prospective, randomized, controlled, blind clinical trials. Another important consideration was the use of venography to determine the presence of deep venous thrombosis.
  
  
  RESULTS
  Various therapies are available for the prevention of postoperative thromboembolic complications. Effective pharmacologic treatments currently available include adjusted-dose heparin, warfarin, aspirin, dextran, and low-molecular-weight heparins (LMWHs). Until recently, warfarin was considered the drug of choice for thromboprophylaxis in high-risk patients, including patients undergoing orthopedic surgical procedures. Because of their comparable efficacy and greater ease of use, LMWHs are gaining favor over warfarin in this patient population. In well-designed clinical trials involving patients undergoing elective total hip replacement or fractured hip surgery, danaparoid has demonstrated greater efficacy than other active treatments, including warfarin, dextran, aspirin, and heparin plus dihydroergotamine. While studies comparing danaparoid with LMWHs have not yet been published, danaparoid may be more useful in patients with heparin-associated thrombocytopenia.
  
  
  CONCLUSIONS
  Danaparoid is an antithrombotic agent with characteristics that distinguish it from heparin and LMWHs. Based on the efficacy and safety data reviewed, danaparoid should be considered one of the drugs of choice for the prevention of thromboembolic complications in patients undergoing orthopedic hip procedures and the drug of choice for the management of any patient with heparin-induced thrombocytopenia who requires anticoagulant therapy.
authors.affiliation: National Pharmacotherapy Institute, Germantown, TN 38183, USA.
authors.forename: V A
authors.initials: VA
authors.lastname: Skoutakis
mesh_terms: D002809:Chondroitin Sulfates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D006493:Heparin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid